DOCSLIB.ORG

Back Matter (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Back Matter (PDF) AUTHOR INDEX Abadla, A. R., 197 Bowers, Gary D., 724 Chung, Woon-Gye, 1263 Eddershaw, Peter J., 724 Abbott, Frank S., 1383 Boyd, Michael R., 651 Clank, B., 922 Edwards, Robert J., 929 Abdallah, Claude, 584 Bozler, Gerhard, 1206 Clarke, Stephen E., 251 Ehlhardt, William J., 910 Acheampong, Andrew A., 708 Bracken, William, 736 Coassolo, P., 1051 Ehninger, Gerhard, 94 Adams, Delyth A., 929 Bradbury, Alan, 393 Coldham, N. G., 501 Ekins, Sean, 1274 Adams, Paula C., 982 Brady, Alexandra N., 60 Collins, Michael A., 102 Elder, Cheryl A., 776 Ader, Jean-Claude, 813 Brashear, Wayne T., 1202 Colthup, P. V., 1225 Elfarra, Adnan A., 846 Agen, Cristiana, 713 Brendel, K., 497 Conroy, Robert, 904 Ellis, Andrew G., 363 Aigbirhio, Franklin I., 832 Brendel, Klaus, 327 Cooper, A. E., 922 Ellis, Joan D., 688 Albet, Carlos, 976 Brennan, Beverley, 349 Coutts, Ronald T., 525 Ellis, Martin K., 102 Ali, Syed F., 881 Brewer, T. 0., 1, 18 Creveling, Cyrus R., 430 El Mansouri, S., 227 Anari, M. Reza, 536 Brien, James F., 1248 Cribb, Alastair, 671 Endo, Takahiko, 1022 Anders, M. W., 48, 124, 875 Bugelski, Peter J., 1044 Cribb, Alastair E., 406, 536 Escousse, Andr#{233},343 Anderson, Christopher D., 1286 Buhler, Donald R., 1263 Crom, William R., 1110 Estabrook, R. W., 765 Anderson, Kathleen, 799 Bull, Richard J., 1412 Crooks, Peter A., 1175 Evans, Frederick E., 1417 Andersson, Paul, 137 Bullock, Peter, 736 Crowl, Robert, 904 Evans, William E., 1 1 10 Andrews, Paul A., 178 232 Burka, Leo T., Crowley, Jan R., 786 Anglada, Lluis, 976 Burke, M. Danny, 1274 Facchine, Kevin L., 869 Cutler, N. Shame, 595 Angus, P. W., 485 Burlingame, Alma L., 369 Fagliano, Jerald A., 607 Faiman, Morris D., 1153 Appleton, Martin L., 595 Burmaster, Steve D., 631 Dahl, A. R., 529 Falany, Charles N., 945 Arison, Byron H., 266 Buronfosse, Thierry, 160 Danesi, Romano, 713 Astrom, Anders, 137 Busch, Ulrich, 1206 Fasanmade, Adedigbo A., 573 Dannecker, Robert, 321, 327 Fasco, Michael J., 1339 Atta-Asafo-Adjei, E., 1431 Buters, Jeroen T. M., 696 Dave, M., 501 Augustijns, Patrick F., 1372 Fedorov, Ivan I., 655 Davies, Donald S., 929 Fenselau, Catherine, 119 Cannell, Richard J. P., 724 Davies, Malonne I., 1072 Ferrero, J. L., 765 Baba, Takahiko, 1195 Carbonaro, Michael A., 1044 Davis, Charles B., 1028, 1044 Ferrero, James L., 1143, 1163 Bader, Augustinus, 1315 Carlson, Timothy J., 749 Dawson, Michael J., 724 Finkelstein, Martin B., 124 Bai, Xigeng, 993 Carrel, Barb K., 757 Dean, Dennis C., 1126 Finley, Brent, 607 Bailey, G. S., 965 Cashman, John R., 1143 de Bruijn, E. A., 433 Fischer, VoWer, 327 Baker, Max T., 60 Castagnoli, Neal, Jr., 749 De Francesco, L., 197 Fisher, M. B., 1431 Balani, Suresh K., 185, 266, 688 Castell, Jos#{233}V., 553 De Graeve, Jean, 1305 Fisher, Robert A., 415 Baron, Jeffrey, 1346 Castillo, Marta, 566 de Groot, M. J., 667 Fisher, Robyn L., 327 Barton, H. A., 1202 Castle, Pamela J., 1037 DeHart, Peter D., 441 Fong, Kei-Lai, 799 Bazin-Redureau, M., 1400 Catlow, John, 916 Dekant, Wolfgang, 861 Fortin, R., 1325 Beauchamp, Lilia, 1242 Cerniglia, Carl E., 1417 Delatour, Paul, 160 Foster, David J. R., 892 Bellward, Gail D., 1407 Chakravarty, Prasun K., 207 de Leon, Jesus H., 1354 Foumel-Gigleux, Sylvie, 1305 Bend, John R., 577 Chang, I. Y., 529 del Tacca, Mario, 713 Franklin, Michael R., 1379 Benet, Leslie Z., 369, 825, 900, Chang, Tsun, 441 de Miranda, Paulo, 1242 Fredenbung, Andrea M., 1178 1099 Chapelle, P., 1400 Demuth, Sandra 0., 1028 Freeman, James P., 1417 Benfenati, E., 113 Chauret, N., 65, 1325 De Sousa, G., 1051 Freemantle, Christopher A. J., 832 Benoit, Etienne, 160 Chay, Sylvia H., 916 Freund, Stefan, 94 Bergeron, Raymond J., I 1 17 Chen, Guangping, 1346, 1390 De Sousa, Georges, 308 Friesen, R., 1325 Besner, Jean Guy, 584 Chen, 1-Wu, 266, 730 Dickinson, Ronald G., 119 Fujii, Y., 28 Bhagwat, Shripad V., 651 Chen, Roger, 207 Dimova, Hnistina, 1117 Ding, Andreas, 369 Fujikawa, A., 28 Bhalla, Kapil N., 506 Chenery, Richard, 349 Fujio, Nami, 999 Bhargava, Ravi, 1110 Chenery, Richard J., 251 di Paolo, Antonello, 713 Fujioka, M., 28 Bijloo, G. J., 667 Cheng, Lawrence K., 631, 806 Distefano, Emma W., 201, 610 Fujisawa, Masae, 1022 Binienda, Zbigniew, 881 Cheraghali, A. Majid, 223 Divakaruni, Prasanna, 295 Fujita, Shoichi, 1268, 1301 Binkley, Shelly N., 1231 Chesson, S. M., 951 Dixon, C. M., 1225 Fujitsu, T., 28 Birner, Gerhard, 861 Chiba, Masato, 622 Dolan, M. Eileen, 1394 Fukuyama, Takako, 779 Bischer, Alfred, 900, 1099 Chikai, Toshiyuki, 35 Domergue, Jacques, 1253 Funae, Yoshihiko, 610, 999 Bishop, Warren P., 299 Ching, Michael S., 190 Donato, M. Teresa, 553 Furst, Sylvia M., 590 Blake, P., 433 Chiu, Shuet-Hing Lee, 207, 1126 Draile, Henning, 1315 Blake, Timothy, 799 Cho, Arthur K., 201, 610 Draper, Alison, 736 Galceran, M. Teresa, 976 Blanz, Joachim, 94 Cho, Joon H., 840 Dreyer, Geoffrey, 799 Gandolfi, A. J., 497 Boado, Ruben J., 55, 1297 Cho, Joo Youn, 460 Dubd, D., 1325 Ganguly, Tanmoy C., 945 Bocci, Guido, 713 Cho, Yong-Baik, 1280 Ducharme, Y., 65 Gargas, Michael, 607 Bockbrader, Howard N., 441 Choudhuri, Supratim, 1291 Duescher, Renee J., 846 Garland, William A., 904 Boehlert, C. C., 1225 Choudhury, Ruksana, 314 Duffel, Michael W., 1346 Garton, Kyle J., 1426 Bonfils, Claude, 1253 Chouini-Lalanne, Nadia, 813 Duha.rt, Benjamin, Jr., 1417 Garver, Eric, 799 Borchardt, Ronald T., 1372 Chow, Moses S. S., 449 Dulik, Deanne M., 1004 Geerts, Rita J. F., 216 Born, Stephanie L., 702 Christians, Uwe, 1315 Du Souich, Patrick, 279, 584 Gerstenberg, B., 143 Bornheim, Lester M., 825 Chu, Chung K., 655 Dwoskin, Linda P., 1175 Ghabrial, H., 485 Boudinot, F. Douglas, 655, 1368 Chu, Teresa Y. Y., 201 Dwyer, Lynn M., 688 Ghabrial, Hany, 190 1436 AUTHOR INDEX 1437 Gilard, Veronique, 813 Holland, Mary L., 90 Kim, Dae-Kee, 1280 Lin, Jiunn H., 266, 730, 1008 Gullet, Gerard, 1253 Hollenberg, Paul F., 786 Kim, Hyesook, 818 Lin, Lena Y., 201, 610 Girard, Y., 1325 Honchel, Ronald, 398 Kim,HyoJ., 840 Ling, Kah-Hiing J., 631 Gires, P., 1400 Hook, Robert H., 631 Kim, Kelly Y., 825 Lipe, George, 881 Gochield, Michael, 607 Hone, Toshiharu, 999 Kim, Key H., 1280 Lipscomb, J. C., 1202 G#{243}mez-Lechdn, M. Jos#{233},553 Horton, M. N., 377 Kim, S. G., 529 Liu, Thao Chao, 246 Gonschior, Ann-Katrin, 1315 Hoshi, Hidenobu, 1301 Kim, Sang Geon, 460 Logan, C. J., 922 Gonzalez, Frank J., 696 Hosokawa, Masakiyo, 1022 Kimelman, David, 72, 83 Loi, Cho-Ming, 1335 Gordon, John D., 1383 Houston, J. Brian, 349, 393 King, Andrew R., 119 Loizou, George D., 875 Goudonnet, Herv#{233},343 Houtman, Jon, 398 Klaassen, Curtis D., 840 Longin-Sauvageon, Christiane, Graham,P.J., 501 Huang, Zeqi, 1339 Kleiner, Heather E., 1136 160 Green, Mitchell D., 299 Hughes, J. Michael B., 832 Klekotka, Paul A., 1434 L#{248}nning,P. E., 377 Green, Trevor, 102 Huskey, Su-Er W., 1126 Knaggs, Andrew R., 724 Lorenzon, Giocondo, 308 Griffin, D. A., 965 Knaus, Edward E., 223 Lu, D. Robert, 1368 Griffin, Gear#{243}idP., 406 Ichimura, Fujio, 1220 Kocarek, Thomas A., 415, 681 Lu,Y.H., 154 Griffm, Robert J., 232 Idowu, 0. R., 1, 18 Kolars, Joseph C., 1315 Luchetta, Gabriel, 1117 Grimm, Scott W., 577 Iga, Tatsuji, 718 Korzekwa, Kenneth R., 696 Lunte, Craig E., 1072 Guaitani,A., 197 Imaoka, Susumu, 999 Kracko, D. A., 529 Guengerich, F. Peter, 285, 438, Inazawa, Kazuhiru, 35 Kraft, Joan Creech, 72, 83, 1058 Machinist, Joseph M., 1163 1315, 1339 Innocenti, Federico, 713 Krasny, Harvey C., 1242 Macleod, Michael C., 854 Guertler, Joseph, 327 Inoue, Katsuhiro, 430 Krasnykh, Victor, 945 Madan, Ajay, 1153 Guo, Zuyo, 438 Iwaki, Masahiro, 900, 1099 Krenitsky, Thomas A., 1242 Madden, Stephen, 929 Gupta, Elora, 1394 Iwasaki, K., 28 Kukulka, M. J., 765 Madhu, Cherukury, 840 Gupta, N., 1085 Iwata, Nobuhisa, 1022 Kukulka, Michael J., 1143 Maes, R. A. A., 433 Guzelian, Philip S., 415 Iyer, Krishna R., 749 Kumagai, Yoshito, 610 Magdalou, Jacques, 343, 1305 Kumar, Gondi N., 506, 1286 Magistrelli, A., 1 13 Hackbarth, Ingelore, 1315 Jaeck, D., 1051 Kumar, Rakesh, 223 Mahle, D. A., 1202 Hall, Caroline, 1383 Jamali, Fakhreddin, 240 Kummer, Michael, 1206 Malet-Martino, Marie-C., 813 Hall, M., 922 Jarvi, Eric J., 1335 Kunze, Kent L., 490, 659 Manchee, Gary R., 724 Hall, Tse Wai, 1188 Jennerwein, Margreth, 178 Kuo, Be-Sheng, 757 Mangold, James B., 615 Halm, Kathy A., 869 Jeong, Hye Gwang, 285 Kuo, Chung-Liang, 935 Manouilov, Konstantine K., 655 Halpert, James R., 577, 702, 1434 Jesthi, Pradipta K., 595 Kuo, George Y., 1004 Mansi, J., 433 Hamaguchi, Tomoyuki, 35 Jimmo, Sandra L., 1248 Kwan, Eddie, 1383 Marchant, Nicola C., 1274 Hamdoune, Mohamed, 343 John, Gilbert H., 702 Kwok, Deborah C., 1028 Marks, Gerald S., 1248 Hansen, K. T., 667 Johnson, John T., 60 Martell, Karen J., 1354 Hanson, Beverly J., 441 Johnson, Ted, 916 Labroo, Rita B., 490 Martinet, M., 1400 Hara, Shuichi, 1022 Jones, A. Daniel, 129, 422 La Du, Bert N., 935 Martino, Robert, 813 Hardwick, James P., 696 Jones, Jeffrey P., 749 Lake, B. G., 501 Masgrau, Elisabeth, 887 Harlow, Greg R., 702 Jones, Terry, 832 Lam, Gilbert N., 603 Masmoudi, Taoufik, 343 Harper, P. G., 433 Jdnsson, Gunilla, 137 Lambert, C., 922 Maspeis, L., 676 Harrell, Andrew W., 251 Jordan, M. C., 922 Lam#{233},Michael W., 129, 422 Masubuchi, Yasuhiro, 999 Hart, Timothy K., 1028 Joseph, Gerald, 799 Lamiable, D., 988 Masuda, Makihiko, 1268, 1301 Harvison, Peter J., 107 Juchau, Mont R., 72, 83, 1058 Lampen, Alfons, 1315 Mathai, Leena, 266 Hashmi, Mazzaz, 1362 Jung, Ki Hwa, 460 Lang, Nicholas P., 518 Mather, Laurence E., 334 Hata, T., 28 Jusko, William J., 573 Lash, Lawrence H., 846 Mathews, Brad S., 757 Hawksworth, Gabrielle M., 1274 Lau, Serrine S., 1136 Matsubara, Takashi, 1195 Hayes, Karen A., 349 Kadlubar, Fred F., 518 Laurenzana, Elizabeth M., 271 Matsuda, H., 28 Hayes, Michael, 832 Kadono, Kyoko, 35 Lavrijsen, Karel, 354 Matsunaga, Tamihide, 261 He, Minxia, 659 Kaltenbach, M., 988 Lawton, M.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Ebrotidine Catalog Number : T15195 CAS Number : 100981-43-9 Molecular Formula : C14H17BrN6O2S3 Molecular Weight : 477.42 Description: Ebrotidine is a competitive H2-receptor antagonist (Ki: 127.5 nM). It has a potent antisecretory activity and evidenced gastroprotection. Storage: 2 years -80°C in solvent; 3 years -20°C powder; DMSO 100 mg/mL (209.46 mM), Need Solubility ultrasonic ( < 1 mg/ml refers to the product slightly soluble or insoluble ) Receptor (IC50) Others In vitro Activity Ebrotidine displaced 3H-thiotidine specific binding to histamine H2-receptors (Ki: 127.5 nmol/l), showing a higher affinity (p < 0.05) than ranitidine (Ki: 190.0 nmol/l) and cimetidine (Ki: 246.1 nmol/l) [1]. In vivo Activity Ebrotidine inhibited histamine- and pentagastrin-stimulated acid secretion in a dose-dependent manner (ED50: 0.21 and 0.44 mg/kg, respectively), following intravenous administration to rats [2]. Results of the macroscopic assessment revealed that ebrotidine at doses of 50mg and higher/kg body weight effectively prevented mucosal injury and that the maximal protective effect was achieved by 1h. Physicochemical analysis established that ebrotidine evoked 30% increase in mucus gel dimension, and showed a 20% increase in phospholipids, and the content of sulfo- (18%) and sialomucins (21%) [4]. The mean number of gastric erosions seen at endoscopy after treatment with ebrotidine plus ASA (2.0 +/- 0.3) was obviously lower than that after placebo plus ASA (3.7 +/- 0.2). This reduction in lesion core by ebrotidine was accompanied by a significant increase in gastric blood flow (by 15% in corpus and 26% in antrum), by a rise in transmucosal potential difference (by 12%), and by a decrease of mucosal micro bleeding [3].
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Induced Liver Injury
    A Wholly-Owned Subsidiary of Frontage Laboratories, Inc. Novel BSEP and MDR3 Inhibition Assays for Investigating Drug- Induced Liver Injury Kan He, PhD Outline • BSEPcyte®: BSEP inhibition format • MDR3cyte®: MDR3 inhibition format Why BSEP • Physiologically important: BSEP is the primary mechanism for export of bile salts – The driving force for bile salt enterohepatic recirculation and bile flow – “Vacuum cleaner” to maintain low intracellular level of bile salts • Validated target with clinical phenotype: BSEP mutations lead to human liver diseases – Progressive Familial Intrahepatic Cholestasis 2 (K903X, Intron 4 (+3)A>C) • Liver failure, death – Benign Recurrent Intrahepatic Cholestasis type 2 (E297G, R432T, V444A) – Associated with intrahepatic cholestasis of pregnancy • BSEP inhibition associated with Drug induced liver injury (DILI) DILI accounts for >50% acute liver failures, and is the leading cause of failures in drug development, boxed warnings on marketed drugs, and market withdrawals of approved drugs. Inhibition of BSEP and MDR3 is one of the underlying mechanisms for DILI. It has been an important task to develop physiologically relevant, reliable, higher throughput assays to determine the inhibition of BSEP and MDR3. Biotranex – Accurate. Efficient. Innovative Why BSEPcyte® • To address concerns about • BSEPcyte® is a physiologically other BSEP inhibition assays relevant, hepatocyte-based, – BSEP-transfected Sf9 insect cell high throughput assay membrane vesicles • Artificial membrane uptake system – Primary hepatocytes in • Incapable of evaluating BSEP suspension inhibition by metabolites • Physiologically relevant • Questionable physiologically – IVIVC relevance • Efflux – Human sandwich-cultured • hepatocytes In-situ metabolism • Reproducible, sensitive, dynamic • Technical challenges range • Low throughput • Flexible – Others • High-throughput • BSEP and sodium taurocholate transporter co-transfected kidney cells • Species comparison • Xenopus laevis oocytes • Canalicular membrane vesicles (CMV) Cheng Y, et al.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]